
	Where results make sense

Topic: Fosrenol

In the News (Wed 30 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	End-stage renal disease: higher dose formulation of Fosrenol approved to reduce serum phosphorus
		Fosrenol is indicated to reduce serum phosphorus in patients with ESRD.
		Fosrenol, a non-calcium phosphate binder, which received FDA approval in October 2004 to reduce serum phosphorus in patients with end-stage renal disease, is formulated as an easy-to-use, chewable only tablet that can be taken without water, an important consideration for ESRD patients who must restrict their fluid intake.
		Fosrenol is available in 250 mg, 500 mg, 750 mg and 1.0 g strengths and the recommended initial daily dose is 750 mg to 1.5 g for adults; physicians should adjust the dose to reach target serum phosphorus levels.
	www.xagena.it /news/medicinenews_net_news/03c4207fa67ee3ea4f42c748980eda86.html (987 words)

	Fosrenol Does Not Further Impact Cognitive Function Deterioration In CKD Stage 5 Patients
		FOSRENOL is not indicated for the treatment of secondary hyperparathyroidism, vascular and nonvascular calcification, or cardiovascular or renal disease.
		FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).
		FOSRENOL is available in a broad range of dosage strengths, including the reformulated strengths of 500 milligrams (mg), 750 mg and 1.0 gram (g), as well as the original 250 mg.
	www.medicalnewstoday.com /medicalnews.php?newsid=54593&nfid=rssfeeds (1614 words)

	Higher Initial Doses of FOSRENOL Result in More Rapid Control of Mean Serum Phosphorus
		FOSRENOL (lanthanum carbonate) is indicated to reduce serum phosphate in patients with end stage renal disease.
		FOSRENOL is formulated as an easy-to- use, unflavored, chewable-only tablet that can be taken without water, an important advantage for ESRD patients who must restrict their fluid intake.
		FOSRENOL is now available in a broader range of dosage strengths, including the newly formulated higher strengths of 750 milligrams (mg) and 1.0 gram (g), as well as the original 250 mg and 500 mg strengths.
	www.rxpgnews.com /research/pharmacology/metals/lanthanum/article_4130.shtml (1659 words)

	Fosrenol does not further impact cognitive function deterioration in CKD Stage 5 patients
		FOSRENOL is not indicated for the treatment of secondary hyperparathyroidism, vascular and nonvascular calcification, or cardiovascular or renal disease.
		FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease (ESRD).
		FOSRENOL is available in a broad range of dosage strengths, including the reformulated strengths of 500 milligrams (mg), 750 mg and 1.0 gram (g), as well as the original 250 mg.
	www.omniomix.com /inthenews.php?id=66837 (1487 words)

	Shire Pharmaceuticals boosted by first Fosrenol approval
		Fosrenol (lanthanum carbonate) is a treatment for high phosphate levels in the blood that occur in patients undergoing dialysis as a result of chronic kidney failure.
		Fosrenol will nevertheless, face direct competition in the shape of Genzyme’s Renagel, which generated around $160m in revenue in 2002, capturing a 40-45% share of the US market.
		Fosrenol is expected to demonstrate strong uptake and Datamonitor forecasts sales of $101m by 2008.
	www.bioportfolio.com /news/datamonitor_59.htm (772 words)

	FOSRENOL (R) maintains bone health status of end-stage renal disease patients
		The effectiveness of FOSRENOL® in reducing serum phosphorus in ESRD patients was demonstrated in one short-term, placebo-controlled, double-blind dose-ranging study, two placebo-controlled randomized withdrawal studies and two long-term, active-controlled, open-label studies in both hemodialysis and peritoneal dialysis (PD) patients.
		One hundred forty-four patients with chronic renal failure undergoing hemodialysis and with elevated phosphate levels were randomized to double-blind treatment at a fixed dose of lanthanum carbonate of 225 mg (n=27), 675 mg (n=29), 1350 mg (n=30) or 2250 mg (n=26) or placebo (n=32) in divided doses with meals.
		FOSRENOL® is indicated to reduce serum phosphate in patients with end-stage renal disease.
	www.eurekalert.org /pub_releases/2004-10/pn-fm102904.php (3289 words)

	Fosrenol Information from Drugs.com
		Fosrenol is used for reducing phosphate levels in patients with end stage renal disease.
		Fosrenol is in the FDA pregnancy category C. This means that it is not known if it will be harmful to an unborn baby.
		Fosrenol should be used exactly as your doctor has prescribed it for you.
	www.drugs.com /fosrenol.html (978 words)

	Fosrenol New Drug Application
		Fosrenol (lanthanum carbonate) is a novel phosphate binder that reduces high blood levels of phosphorus in End-Stage Renal Disease (ESRD) patients on dialysis.
		Fosrenol works by binding to dietary phosphate in the GI tract; once bound, the Fosrenol/phosphate complex cannot pass through the intestinal lining into the blood stream and is eliminated from the body.
		This programme has demonstrated that Fosrenol is an effective phosphate binder with a proven safety profile for long-term use.
	www.drugs.com /NDA/fosrenol_040720.html (762 words)

	News - Fosrenol Significantly Reduces Tablet Burden for End-Stage Renal Disease Patients With Hyperphosphatemia and ...
		Fosrenol (lanthanum carbonate) is indicated to reduce serum phosphate in patients with end stage renal disease.
		Fosrenol is formulated as an easy-to- use, unflavored, chewable-only tablet that can be taken without water, an important advantage for ESRD patients who must restrict their fluid intake.
		Fosrenol is now available in a broader range of dosage strengths, including the newly formulated higher strengths of 750 mg and 1.0 g, as well as the original 250 mg and 500 mg strengths.
	www.docguide.com /news/content.nsf/news/852571020057CCF6852571570047B4D3 (1504 words)

	Buy cheap Fosrenol Chewable Tablets Drug Information Fosrenol Chewable Tablets (Site not responding. Last check: 2007-10-06)
		The effectiveness of FOSRENOL® in reducing serum phosphorus in ESRD patients was demonstrated in one short-term, placebo-controlled, double-blind dose-ranging study, two placebo-controlled randomized withdrawal studies and two long-term, active-controlled, open-label studies in both hemodialysis and peritoneal dialysis (PD) patients.
		One hundred forty-four patients with chronic renal failure undergoing hemodialysis and with elevated phosphate levels were randomized to double-blind treatment at a fixed dose of lanthanum carbonate of 225 mg (n=27), 675 mg (n=29), 1350 mg (n=30) or 2250 mg (n=26) or placebo (n=32) in divided doses with meals.
		FOSRENOL® is indicated to reduce serum phosphate in patients with end-stage renal disease.
	xya.ru /buy/Fosrenol_Chewable_Tablets.html (2661 words)

	Fosrenol (Lanthanum Chewable Tablets) : Buy Fosrenol (Lanthanum Chewable Tablets) at ABC Online Pharmacy
		Fosrenol (Lanthanum Chewable Tablets) is a medication used to treat hyperphosphatemia in dialysis patients with ESRD.
		Fosrenol (Lanthanum Chewable Tablets) is used for reducing serum phosphate in patients with end stage renal disease.
		Fosrenol (Lanthanum Chewable Tablets) is in the FDA pregnancy category C. This means that it is not known whether Fosrenol will be harmful to an unborn baby.
	www.abconlinepharmacy.com /ns/customer/product4133-c-p1 (1004 words)

	Newly Approved Drug Therapies (871): Fosrenol, lanthanum carbonate, Shire Pharmaceuticlas
		Fosrenol is supplied as a chewable tablet of two dosage strengths (250 mg and 500 mg), and is designed to be taken with or immediately following meals.
		FDA approval of Fosrenol for the treatment of hyperphosphatemia in ESRD was based on a total of 5 clinical trials: 3 were placebo controlled, including 1 short-term, double-blind dose-ranging study and 2 randomized withdrawal studies; and 2 were active-controlled, both long-term, open-label studies in both hemodialysis and peritoneal dialysis (PD) patients.
		Fosrenol demonstrated a non-inferior reduction in serum phosphate levels (roughly 1.8 mg/dL for all medications), and maintenance of these levels with Fosrenol was extablished for up to three years in long-term, open label extensions.
	www.centerwatch.com /patient/drugs/dru871.html (846 words)

	First Approval for FOSRENOL
		FOSRENOL is a new medicine that helps control phosphate levels in patients who require dialysis for severe kidney disease.
		FOSRENOL is a treatment for high phosphate levels in the blood (hyperphosphataemia) that occurs as a result of chronic kidney failure.
		For clinicians and patients alike FOSRENOL will, we believe, represent a milestone as an effective and well-tolerated alternative to current therapies." Submissions have also been made by Shire to gain marketing approvals for FOSRENOL in the United States where estimates indicate there are approximately 270,000(1,3) dialysis patients.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/03-24-2004/0002133836&EDATE= (936 words)

	BioWorld Today
		The latest player on the field is Fosrenol (lanthanum carbonate), from Shire Pharmaceuticals Group plc, approved by the FDA in October - a move that triggered an $18 million licensing payment to AnorMed Inc., per their agreement.
		One of the reasons for the Fosrenol plateau cited by Baird is the cost-benefit ratio.
		On the labels, Renagel's phosphorous-lowering capability is said to surpass that of Fosrenol, despite earlier excitement about the latter as a new and apparently better drug, the Baird report said.
	www.bioworld.com /servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=35157 (959 words)

	PRNewswire do Brasil
		Treatment with FOSRENOL for 2 years had no adverse effects on bone histology and was not associated with an increased incidence of osteomalacia (bone softening).
		Shire is proud of this comprehensive data which support the benefits FOSRENOL can bring to patients with CKD on dialysis.' These studies are promising news for the estimated 1.4 million people on dialysis worldwide(3) who are at risk from the serious consequences of hyperphosphataemia, shown to be associated with long-term morbidity and mortality(4).
		As FOSRENOL is associated with a lower tablet burden than existing phosphate binders (as few as one pill per meal), it may offer simplified dosing for these patients(10).
	www.prnewswire.com.br /news/061100000161.htm (1464 words)

	Fosrenol Consumer Information
		Fosrenol is a medicine used to reduce buildup of phosphates in patients with end-stage kidney disease.
		Small amounts of phosphates are needed by all cells in the body for them to work the right way.
		Fosrenol mixes with phosphates from food in the stomach to stop the phosphates from passing into the body.
	www.fda.gov /cder/consumerinfo/druginfo/fosrenol.htm (274 words)

	ANTARA News :: Fosrenol(R) Demonstrates Effective Phosphate Control With as Few as Three Tablets a Day
		A total of 359 dialysis patients were treated with FOSRENOL as monotherapy and were available for analysis from this multicentre, open label study, following a switch from their previous binder therapy.
		Further data presented at the ERA-EDTA Congress showed that treatment with FOSRENOL was associated with a high level of patient and physician satisfaction, based on a number of assessments and linked to a reduction in tablet burden(2).
		FOSRENOL has been available in the US for 18 months with over 44,000 patients receiving Fosrenol since launch and will continue to be launched across Europe in the remainder of 2006 and into 2007.
	www.antara.co.id /en/arc/2006/7/19/fosrenolr-demonstrates-effective-phosphate-control-with-as-few-as-three-tablets-a-day (1520 words)

	Fosrenol Approval / Fosrenol Approval / Tricor (Site not responding. Last check: 2007-10-06)
		FDA approval of Fosrenol for the treatment of hyperphosphatemia in ESRD was based on a total of 5 clinical trials: 3 were placebo controlled,...
		Shire Pharma Fosrenol Approval As Expected Nov 29, 2005 1306 GMT Shire Pharmaceutical's (SHPGY) approval from the FDA for a higher dose...
		Fosrenol is a treatment for high phosphate levels in the blood, which occur in patients undergoing dialysis as a result of chronic kidney failure.
	fosrenol.pharmacy-world.biz /fosrenol_approval (956 words)

	AEGiS-PRn: AnorMED announces Foznol(TM) NDA submitted to FDA
		Shire anticipates that the U.S. will be the largest market for Fosrenol and, pending FDA regulatory approval, we look forward to seeing this product made available to the many patients who need it.
		It is estimated that there are approximately 280,000 kidney dialysis patients in the U.S., 225,000 in Europe, 190,000 in Japan and 90,000 in the Pacific Rim region.
		Fosrenol, developed as a convenient chewable tablet, binds to the dietary phosphate in the digestive system.
	www.aegis.com /news/pr/2002/PR020462.html (772 words)

	Shire Acquisition First Approval for FOSRENOL
		FOSRENOL is a new medicine that helps control phosphate levels in patients who require dialysis for severe kidney disease.
		Assuming a positive response from other regulatory authorities, FOSRENOL should be available in other countries in the European Union during the second half of the year.
		FOSRENOL is a treatment for high phosphate levels in the blood (hyperphosphataemia) that occurs as a result of chronic kidney failure.
	www.advfn.com /news_first-approval-for-fosrenol_7195578.html (1001 words)

	Fosrenol Availability / Fosrenol / Certican (Site not responding. Last check: 2007-10-06)
		Fosrenol is indicated to reduce serum phosphorus in patients with ESRD.
		Fosrenol® Discussion was deferred to a discussion of the class of Electrolyte...
		FOSRENOL is currently available in the US and will be launched across Europe over.
	fosrenol.pharmacy-world.biz /fosrenol___availability (839 words)

	Fosrenol \| Online Pharmacies Canada
		Fosrenol (Lanthanum Carbonate) isa first line calcium free and aluminum free phosphate binder that helps lower serum phosphate levels.
		Fosrenol provides maintenaince with as few as 3 tablets per day.
		Fosrenol is chewable only, which is great news for patients trying to watch their fluid intake.
	www.onlinepharmaciescanada.com /Fosrenol/15166.aspx (84 words)

	ANTARA News :: New Analyses Demonstrate Positive Effect on Bone With FOSRENOL(R) Treatment Compared With Standard T
		FOSRENOL's therapeutic profile is further reinforced by the publication of new cognitive function data in Kidney International this month(2).
		These studies are promising news for the estimated 1.4 million people on dialysis worldwide(3) who are at risk from the serious consequences of hyperphosphataemia, shown to be associated with long-term morbidity and mortality(4).
		FOSRENOL has been available in the US for 22 months with over 53,000 patients receiving Fosrenol since launch.
	www.antara.co.id /en/arc/2006/11/20/new-analyses-demonstrate-positive-effect-on-bone-with-fosrenolr-treatment-compared-with-standard-t (1570 words)

	La FDA aprueba el uso de Fosrenol (carbonato de lantano) para controlar los niveles de fosfato sérico en pacientes con ...
		Los pacientes tratados con FOSRENOL en los estudios clínicos alcanzaron una reducción rápida y significativa de la concentración sérica de fósforo en la primera semana de tratamiento7, llegando a las concentraciones diana antes de ocho semanas.
		FOSRENOL es un tratamiento muy necesario para los pacientes con enfermedad renal terminal, ya que menos de un tercio de ellos puede controlar las concentraciones de fosfato con los medicamentos existentes.
		FOSRENOL actúa uniéndose al fosfato de la dieta en el tracto GI; una vez unido, el complejo FOSRENOL/fosfato no puede atravesar la pared intestinal hacia el torrente sanguíneo y se elimina del cuerpo.
	www.pmfarma.com /noticias/noticias/noti.asp?ref=3835 (690 words)

	AnorMED Inc. - Products: Fosrenol
		FOSRENOL is a novel phosphate binder based on lanthanum carbonate to treat hyperphosphatemia in kidney failure patients.
		FOSRENOL binds to phosphate resulting in the formation of a relatively water insoluble compound, lanthanum phosphate, which cannot pass easily through the gut.
		As FOSRENOL does not contain calcium it enables the physician to separate the control of calcium from phosphate.
	www.anormed.com /products/fosrenol/index.cfm (339 words)

	News - Fosrenol Has Long-Term Safety and Efficacy in End-Stage Renal Disease Patients Treated for up to 6 Years
		Fosrenol®, a non-calcium phosphate binder, which received FDA approval in October 2004 to reduce serum phosphorus in patients with end-stage renal disease, is formulated as an easy-to-use, chewable only tablet that can be taken without water, an important consideration for ESRD patients who must restrict their fluid intake.
		Fosrenol is available in 250 mg and 500 mg strengths and the recommended initial daily dose is 750 mg to 1.5 grams for adults; physicians should adjust the dose to reach target serum phosphorus levels.
		Fosrenol® should not be taken by patients who are under 18 years of age.
	docguide.com /news/content.nsf/news/8525697700573E18852570B90054C47C (1253 words)

Try your search on: Qwika (all wikis)